Rational design of improved pharmabiotics.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Translating priority effects and niche engineering into rational microbiome therapeutics across the gut-lung axis.Frontiers in microbiology · 2026
   Review
2. Common Inflammatory Mechanisms in COVID-19 and Parkinson's Diseases: The Role of Microbiome, Pharmabiotics and Postbiotics in Their Prevention.Journal of inflammation research · 2021
   Review
3. Designer probiotics: Development and applications in gastrointestinal health.World journal of gastrointestinal pathophysiology · 2015
   Review
4. Under the microscope: From pathogens to probiotics and back.Bioengineered · 2015
   Review
5. Metagenomics and novel gene discovery: promise and potential for novel therapeutics.Virulence · 2014
   Review
6. Experimental determination and characterization of the gap promoter of Bifidobacterium bifidum S17.Bioengineered · 2014
   Article
7. Use of ultra high performance liquid chromatography-tandem mass spectrometry to demonstrate decreased serum statin levels after extracorporeal LDL-cholesterol elimination.Journal of biomedicine & biotechnology · 2011
   Article
8. Screening and evaluation of human intestinal lactobacilli for the development of novel gastrointestinal probiotics.Current microbiology · 2010
   Article
9. Probiotic therapy - recruiting old friends to fight new foes.Gut pathogens · 2010
   Article
10. Extracorporeal immunoglobulin elimination for the treatment of severe myasthenia gravis.Journal of biomedicine & biotechnology · 2010
    Article
11. A single point mutation in the listerial betL σ(A)-dependent promoter leads to improved osmo- and chill-tolerance and a morphological shift at elevated osmolarity.Bioengineered
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as